ReviewiScience2026
Following the central dogma: Nanopore sequencing from DNA and RNA to proteins.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first nanopore-based sequencer was launched in 2014, and subsequently, nanopore played an irreplaceable role in disclosing the first complete, gapless sequence of a human genome in 2022 due to its megabase-scale read lengths. However, a striking revelation from DNA sequencing is that over 95% of human DNA does not specify a protein, which means tremendous proteomic information cannot be predicted from the genome. Therefore, nanopore researchers have been leaning increasing attention to the proteome. Nowadays, nanopores have demonstrated unprecedented performance in discriminating individual proteinogenic amino acids with chemical modifications. Meanwhile, diverse strategies for full-length proteins to translocate through nanopores have been developed. Undoubtedly, nanopore will sooner or later facilitate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.